Claire Thompson1
Agility Life Sciences1
The vast majority of new drug candidates are "badly behaved", either poorly soluble, poorly permeable, or both. The pandemic has increased the expectation from patients and investors that we develop medicines more quickly. So, how can we accelerate timelines while also giving drug candidates the best chance of success in preclinical and clinical studies? We will discuss case studies demonstrating how nano-enabled approaches can enable you to formulate fast while also futureproofing your products.